Allosteric c-Abl Inhibitors for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) are ineffective, and there is a need for new therapeutic strategies that can treat or prevent AD and other neurodegenerative diseases associated with c-Abl tyrosine kinase.
Innovation Solution
Development of compounds that inhibit c-Abl tyrosine kinase by binding to its allosteric site, particularly targeting the myristate pocket, and are capable of crossing the blood-brain barrier, administered to treat diseases involving c-Abl tyrosine kinase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then existing therapeutic approaches are maintained, but they are ineffective in treating or preventing AD and other neurodegenerative diseases
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula I) that target the c-Abl tyrosine kinase pathway. The compounds feature specific substituent patterns (R1-R5 groups) and structural parameters (n and m values) that optimize their ability to cross the blood-brain barrier and inhibit c-Abl activity, thereby transforming ineffective current treatments into effective neuroprotective therapy
Solution Approach 2:
The patent uses c-Abl tyrosine kinase as an intermediary target to treat Alzheimer's disease. Instead of directly targeting amyloid plaques or tau tangles, the compounds inhibit c-Abl kinase activity, which mediates downstream effects including neuronal dysfunction and protein aggregation. This intermediary approach provides a new therapeutic pathway that addresses the root causes of neurodegeneration
2Reliability
If compounds are designed to inhibit c-Abl tyrosine kinase by binding to allosteric site, then specific mechanism of action is achieved, but complexity of compound design increases
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the myristate pocket region of c-Abl kinase. The molecular structure (Formula I) features specific functional groups and spatial arrangements concentrated at key interaction points, allowing selective binding to the allosteric site while maintaining overall structural feasibility for drug development
Solution Approach 2:
The patent achieves universality by creating a compound platform (Formula I) that can address multiple aspects of Alzheimer's pathology through a single mechanism. The compounds simultaneously inhibit c-Abl kinase activity, prevent protein aggregation, and protect neurons, providing multi-functional therapeutic effects through one molecular design
3Reliability
If compounds are administered to treat diseases involving c-Abl tyrosine kinase, then therapeutic effect is achieved, but need to ensure compounds can cross blood-brain barrier
Solution Approach 1:
The patent applies parameter changes by optimizing physical and chemical properties of the compounds in Formula I. Specific substituent groups (R1-R5) and structural parameters (n and m) are selected to modify molecular size, lipophilicity, and hydrogen bonding capacity, thereby enhancing blood-brain barrier penetration while maintaining c-Abl inhibitory activity and therapeutic effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit c-Abl tyrosine kinase, reducing neuronal dysfunction, preventing protein aggregation, and improving cognitive decline in AD models, thereby providing a potential therapeutic approach for AD and other neurodegenerative diseases.
Implementation Method 1
the compound inhibits c-Abl tyrosine kinase by binding to an allosteric site of the c-Abl tyrosine kinase. In some embodiments, the compound binds to a myristate pocket of the c-Abl tyrosine kinase
Data Source
AI summary
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.